|
|
| Home | Stock Market Blogs | Financial Tools | Sign Up Free | |
| Northwest Biotherapeutics, Inc. New Common stock | |
||||||||||||||||||||||||||||||||||||||||||||||||||||
| Northwest Biotherapeutics, Inc. New Common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NWBO | Last: $0.99 ($+0.01) | Volume: 314,549 | Last Trade: 8/5/2010 5:20:15 PM | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Today
Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
| Northwest Biotherapeutics, Inc. New Common stock Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Northwest Biotherapeutics is a development stage biotechnology company that focuses on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to treat cancer. Co.'s approach in developing cancer therapies utilizes its knowledge in the biology of dendritic cells, which are a type of white blood cells that activate the immune system. Co. has two basic technology platforms applicable to cancer therapeutics: dendritic cell-based cancer vaccines, which it calls DCVax, and monoclonal antibodies for cancer therapeutics. The DCVax dendritic cell-based cancer vaccine program is Co.'s main technology platform. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Northwest Biotherapeutics, Inc. New Common stock News & Press Releases | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Long-Term Follow-Up of DCVax®-Treated Brain Cancer Patients Shows 33% of Patients Reached 4-Year Sur BETHESDA, Md. , Aug. 3 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") ( NWBO ) today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical tri... [more] Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring BETHESDA, M.D., July 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") ( NWBO ), developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding... [more] Northwest Biotherapeutics Inc. Appoints Market Media Connect as Communications Agency of Record BETHESDA, Md. , Feb. 8 /PRNewswire/ -- Northwest Biotherapeutics, Inc. ( NWBO ), a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Ma... [more] Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Strikin BETHESDA, Md. , Feb. 17 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBT and NWBS) ("NWBT" or the "Company") today announced further long-term follow-up da... [more] Northwest Biotherapeutics Secures $700,000 Equity Financing BETHESDA, Md. , Feb. 10 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBS and NWBT; NWBO ) (the "Company") announces today receipt of $700,000 in cash... [more] Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Actio BETHESDA, Md. , Jan. 8 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBS and NWBT) (the "Company" or "NWBT") announced today settlement of a putative securities... [more] Northwest Secures US$0.5 Million Debt Financing BETHESDA, Md. , Dec. 23 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBS and NWBT), today announced that it has obtained US$0.5 million in deb... [more] Northwest Secures US$1.65 Million Debt Financing BETHESDA, Md. , Nov. 6 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBS and NWBT), today announced that it has obtained US$1.65 million in fun... [more] Northwest Secures US$1.0 Million Debt Financing BETHESDA, Md. , Oct. 2 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBT and NWBS), today announced that it has entered into a Loan Agreement and Promissory... [more] Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Bra BETHESDA, Md. , Sept. 11 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBT and NWBS) ("NWBT" or the "Company") today announced the most recent long-term fol... [more] Northwest Biotherapeutics to Present at Next Generation Vaccine Conference BETHESDA, Md. , July 18 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBS and NWBT; NWBO ), (the "Company or NWBT"), today announced that Dr. Alton L. Boynto... [more] Northwest Secures US$4.0 Million in Debt Financing BETHESDA, Md., May 9 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. NWBO , today announced that Al Rajhi Holdings W.L.L. ("Al Rajhi") has entered into an agreement, executed on May 6 2008, to provide NWBT with debt financing in... [more] |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign Up | Copyright © 2013 SmallCapWatch, LLC. |
| Never invest based soley on information from this website or our e-mail and IM alerts | |
